Catherine Szyman Net Worth

The estimated Net Worth of Catherine M. Szyman is at least $13 Million dollars as of 3 May 2024. Ms. Szyman owns over 5,796 units of Edwards Lifesciences Corp stock worth over $3,345,479 and over the last 10 years she sold EW stock worth over $6,858,666. In addition, she makes $2,794,690 as Corporate Vice President - Critical Care at Edwards Lifesciences Corp.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Ms. Szyman EW stock SEC Form 4 insiders trading

Catherine has made over 63 trades of the Edwards Lifesciences Corp stock since 2016, according to the Form 4 filled with the SEC. Most recently she exercised 5,796 units of EW stock worth $395,577 on 3 May 2024.

The largest trade she's ever made was exercising 80,308 units of Edwards Lifesciences Corp stock on 7 May 2023 worth over $2,660,604. On average, Catherine trades about 5,185 units every 27 days since 2015. As of 3 May 2024 she still owns at least 49,018 units of Edwards Lifesciences Corp stock.

You can see the complete history of Ms. Szyman stock trades at the bottom of the page.

Catherine Szyman biography

Catherine M. Szyman serves as Corporate Vice President - Critical Care of the Company. Ms. Szyman has been Corporate Vice President, Critical Care since 2015. Under her leadership, Edwards has experienced successful sales growth in the Critical Care business unit. Prior to 2015, she was employed for more than 20 years at Medtronic, LLC, where she served as its Senior Vice President and President of Medtronic’s global diabetes business from 2009 to 2014, overseeing research, development, operations, sales and marketing for Medtronic’s insulin infusion pumps and continuous glucose monitoring systems. Prior to that, she held a variety of leadership roles at Medtronic, including Senior Vice President of Corporate Strategy and Business Development, General Manager of Endovascular Innovations and Vice President of Finance for the Cardiovascular Business. Ms. Szyman currently serves on the boards of Endotronix, Octane OC and Inari Medical, Inc. and previously served on the boards of Tornier, Inspire Medical Systems, and the California Healthcare Institute.

What is the salary of Catherine Szyman?

As the Corporate Vice President - Critical Care of Edwards Lifesciences Corp, the total compensation of Catherine Szyman at Edwards Lifesciences Corp is $2,794,690. There are 4 executives at Edwards Lifesciences Corp getting paid more, with Michael Mussallem having the highest compensation of $11,521,000.

How old is Catherine Szyman?

Catherine Szyman is 63, she's been the Corporate Vice President - Critical Care of Edwards Lifesciences Corp since 2015. There are 6 older and 13 younger executives at Edwards Lifesciences Corp. The oldest executive at Edwards Lifesciences Corp is William Link, 74, who is the Independent Director.

What's Catherine Szyman's mailing address?

Catherine's mailing address filed with the SEC is ONE EDWARDS WAY, , IRVINE, CA, 92614.

Insiders trading at Edwards Lifesciences Corp

Over the last 21 years, insiders at Edwards Lifesciences Corp have traded over $94,964,396 worth of Edwards Lifesciences Corp stock and bought 47,398 units worth $3,992,090 . The most active insiders traders include Michael A Mussallem, Donald E Jr Bobo, and Steven R Loranger. On average, Edwards Lifesciences Corp executives and independent directors trade stock every 8 days with the average trade being worth of $1,126,057. The most recent stock trade was executed by Donald E Jr Bobo on 11 September 2024, trading 5,000 units of EW stock currently worth $226,400.

What does Edwards Lifesciences Corp do?

edwards lifesciences (nyse: ew) is the global leader in the science of heart valves and hemodynamic monitoring. driven by a passion to help patients, the company partners with clinicians to develop innovative technologies in the areas of structural heart disease and critical care monitoring that save and enhance lives. headquartered in irvine, california, edwards lifesciences has extensive operations in north america, europe, japan, latin america and asia and currently employs about 6,400 individuals worldwide. for us, helping patients is not a slogan – it's our life’s work. from developing devices that replace or repair a diseased heart valve to creating new technologies that monitor vital signs in the critical care setting, we help ensure that patients regain and even improve their quality of life.

Complete history of Ms. Szyman stock trades at Edwards Lifesciences Corp, Inari Medical, and Outset Medical

Edwards Lifesciences Corp executives and stock owners

Edwards Lifesciences Corp executives and other stock owners filed with the SEC include:

• Michael Mussallem,
  Chairman of the Board, Chief Executive Officer
• Scott Ullem,
  Chief Financial Officer, Corporate Vice President
• Larry Wood,
  Corporate Vice President - Transcatheter Aortic Valve Replacement
• Donald Bobo,
  Corporate Vice President - Strategy and Corporate Development
• Catherine Szyman,
  Corporate Vice President - Critical Care
• Jean-Luc Lemercier,
  Corporate Vice President - EMEA (Europe, Middle East and Africa)
• Michael A. Mussallem,
  Chairman & CEO
• Jean-Luc Lemercier,
  Corp. VP of Europe, Middle East, Africa, Canada & Latin America
• Scott B. Ullem,
  Corp. VP & CFO
• Larry L. Wood,
  Corp. VP of Transcatheter Aortic Valve Replacement
• Donald E. Bobo Jr.,
  Corp. VP of Strategy & Corp. Devel.
• Heisz Stone,
  Independent Director
• William Link,
  Independent Director
• Kieran Gallahue,
  Independent Director
• Steven Loranger,
  Independent Director
• Nicholas Valeriani,
  Independent Director
• Martha Marsh,
  Lead Independent Director
• Paul LaViolette,
  Director
• Ramona Sequeira,
  Director
• Daveen Chopra,
  Corporate Vice President - Surgical Structural Heart
• Huimin Wang,
  Corporate Vice President - Japan, Asia and Pacific
• Christine Z. McCauley,
  Corp. VP of HR
• Dirksen J. Lehman,
  Corp. VP of Public Affairs
• Arnold A. Pinkston,
  Corp. VP & Gen. Counsel
• Mark Wilterding,
  VP of Investor Relations
• Dr. Todd J. Brinton,
  Corp. VP of Advanced Technology & Chief Scientific Officer
• Patrick B Verguet,
  CVP, Europe
• John T Cardis,
  Director
• Schack Wesley W Von,
  Director
• Daniel J. Lippis,
  CVP, JAPAC
• Carlyn D Solomon,
  CVP, Critical Care & Vascular
• David E I Pyott,
  Director
• Michael R Bowlin,
  Director
• Bruce P Garren,
  Corp VP, Gen Counsel & Secty
• Barbara J Mcneil,
  Director
• Robert Alexander Ingram,
  Director
• John H Jr Kehl,
  Corp VP, Strategy & Bus Dev
• Thomas M Abate,
  CVP, CFO and Treasurer
• Christine Z Mc Cauley,
  CVP, Human Resources
• Robert C Reindl,
  Corp VP, Human Resources
• Aimee S Weisner,
  CVP, General Counsel
• Vernon R Jr Loucks,
  Director
• Paul C Redmond,
  CVP, CardioVations Surgcl Sys
• Corinne H Nevinny,
  CVP, Chief Financial Officer
• Philip M Neal,
  Director
• Stuart L Foster,
  Corp VP, Technology/Discovery
• John Alexander Martin,
  CVP, North America
• Anita Bessler,
  Corp VP, Global Franchise Mgmt
• Randel William Woodgrift,
  Corp VP, Manufacturing Ops
• J Randall Nelson,
  Corp VP, North America
• David T Feinberg,
  Director
• Robert W.A. Sellers,
  SVP, Corporate Controller
• Bernard J Zovighian,
  CEO
• Wayne Markowitz,
  GM & SVP, Surgical
• Leslie C. Davis,
  Director